Pharmaceutical
- Pharmaceutical intermediates
- Heterocyclic Compound
- OLED material intermediate
- Diphenylamine intermediates
- Nutritional Supplements
- Pharmaceutical raw materials
Human APIs Powder
- Respiratory Drugs Raw Material
- Antiviral Antibacterial
- Antipyretic Analgesics
- Antihistamine Drugs
- Antineoplastic
- Urinary System Drugs
- Endocrine System
- Other
Medicine Excipients
Veterinary raw materials
Phone: 86-29-89601602
E-mail: sales21@interlgroup.com
Add: Fengcheng 2nd Road, Weiyang District, Xi'an, Shaanxi, China
HRK Supply Methyldopa raw Materials powder
Product Overview:
Methyldopa, antihypertensive, alpha-receptor agonist, commonly used in tablet form. This product is a kind of excitatory vascular movement center alpha-receptor, thereby inhibiting the diplomatic nerve, resulting in hypotensive effect, accompanied by slow heart rate, reduce cardiac output, small artery dilation, peripheral vascular resistance is significantly reduced, long-term application of cardiac output is not significantly reduced. Clinical use for moderate, severe or malignant hypertension, especially for secondary hypertension, pregnancy hypertension, heart failure combined with hypertension, coronary heart disease combined with hypertension and elderly hypertension patients
HRK Supply Methyldopa raw Materials powder Attributes
CAS:555-30-6
MF:C10H13NO4
MW:211.22
EINECS:209-089-2
Specification: 99% min Methyldopa Powder
Sample:Methyldopa Powder
Packaging:1kg/bag, 25kg/drum
Brand: Henrikang
Appearance:white
Storage: Cool Dry Place
Shelf Life: 2 Years
Test Method: HPLC
HRK Supply Methyldopa raw Materials powder Details
Methyldopa Powder Usage and Synthesis.
L-methyldopa is used for moderate, severe or malignant hypertension, especially for renal hypertension or hypertension with poor renal function.
Uses of Methyldopa.
L-methyldopa is a B-block-type cardiovascular drug, which has a good effect on primary and renal hypertension of moderate program.
Combined with fluphenazine and haloperidol, the extrapyramidal adverse reactions were increased. Ibuprofen has antihypertensive effect on methyldopa; Levodopa antagonizes the antitremor paralysis effect of methyldopa; Increased neurotoxicity in combination with lithium. Combined with risepine can intensify central inhibition.
Pharmacological action of Methyldopa.
This product is an aromatine decarboxylase inhibitor. Only the L-isomer of alpha-methyldopa has antihypertensive activity in humans, and the racemic (DL-alpha-methyldopa) requires twice the dose to achieve the same antihypertensive effect. Its antihypertensive effect may be through its active metabolite β-methylnorepinephrine stimulation of central inhibitory β receptors and pseudo-neurotransmitters, reducing plasma renin activity, and thereby reducing arterial blood pressure. Methyldopa can reduce tissue levels of serotonin, dopamine, nomethylepinephrine, and methylepinephrine. It has no direct effect on cardiac function and generally does not reduce glomerular filtration rate, renal blood flow, and filtration fraction. Cardiac output remains constant at normal heart rate, and some patients experience a slowing heart rate. Plasma renin activity decreased during treatment. Methyldopa can reduce decubitus and orthostatic blood pressure, and postural hypotension is rare. Hypotension during daytime exercise is rare.
Product method of Bulk Methyldopa Powder.
Vanillin was methylated to veratrol by dimethyl sulfate, then condensed with nitroethane to obtain 1- (2-nitropropenyl) -3', 4' -dimethoxybenzene, then reduced with iron powder and hydrolyzed to produce 3', 4' -dimethoxyphenylacetone (see 14945), and then DL-methyldopa was obtained by cyclization, ring-opening and hydrolysis. Methyldopa is obtained by separating out the levorotator.
